Can't disagree to an extent. Thing is what is done is done. Hopefully valuable lesson learned for future business dealings. We have to move on.
Here is PART of an email(just general info) I got from Todd Falls today after I sent him Joe, EVH and Joe yet another CV report which left GNBT/NGIO out. They are appreciative of us catching these pieces and sending them there way.
Generex Biotechnology Corp. An integrated life sciences family of companies.
Today’s branches of Generex Biotechnology Corp. (GNBT) The “New” Generex & The NuGenerex Family of Subsidiary Companies Generex and its subsidiary companies have extensive patent portfolios, with intellectual property for composition of matter, formulation, design, and use in a number of therapeutic areas, across multiple indications. As described, we plan to build our legacy assets with the ultimate goal to spin-out such assets at the appropriate time, which have been incorporated into NuGenerex subsidiary companies in an effort to unlock the potential unrealized value of the intellectual property and commercial opportunities for these development companies in major markets for immuno-oncology, diabetes, and infectious disease testing:
• NuGenerex Therapeutics: Oral-lyn (Buccal Insulin) and RaidMist Buccal delivery technology
• NuGenerex Immuno-Oncology: Phase II AE37 + Keytruda in TNBC; Antigen Express (Ii-Key), Licensing, Partnerships, investor dividend paid (1:4) for spin-out
• NuGenerex Diagnostics: NGDx Express II rapid diagnostic tests for infectious disease.
The “New” Generex & The NuGenerex Family of Subsidiary Companies Through reorganization and acquisition, we are building the family of NuGenerex subsidiary companies to provide end-to-end solutions for physicians and patients. To that end, our subsidiary NuGenerex Distribution Solutions (NDS) has established a network of physicians, ancillary service providers, and patients through a Management Services Organization (MSO). As the MSO network currently consists of orthopedic surgeons and podiatrists, we have acquired and/or have agreements to acquire a number of revenue-generating companies that manufacture, market and distribute surgical and wound healing products. The acquisitions include Olaregen Therapeutix, a regenerative medicine company that has recently launched Excellagen wound conforming gel, which is FDA-cleared for the management of 17 wound healing indications, and Regentys, a clinical-stage development company with regenerative medicine technology for the treatment of inflammatory bowel diseases; Pantheon Medical, a manufacturer of patented, FDA-cleared foot & ankle kits with surgical plates, screws, and tools; and MediSource Partners, a licensed distributor of surgical supplies, orthopedic implants, and biologics, including human placental derived tissue products for regenerative medicine applications. Additionally, NDS will be launching a new software as a service (SaaS) business called DME-IQ that enables orthopedic surgeons to manage in-house programs for orthopedic durable medical equipment, including inventory controls, insurance adjudication, and patient billing. Together, under the banner of these subsidiary companies offer a range of products and services to meet the needs of our proprietary distribution channels. Cross selling of products and services will enhance the revenue opportunities for the entire family of NuGenerex subsidiaries.
Our corporate mission is to provide end-to-end solutions for physicians and patients through geographic expansion of our MSO model, diversification of management services offerings, the establishment of an HMO in partnership with Dr. Kiran Patel, and the proposed acquisition of an Accountable Care Organization for complex care.
The NuGenerex family of subsidiary companies offer a broad range of products and services to meet the needs of physicians and patients, including:
• Nugenerex Distribution Solutions: MSO, Ancillary Services, DME-IQ, and Surgical Products.
• NuGenerex Regenerative Medicine: Olaregen Therapetix, Regentys.
• NuGenerex Surgical Products: Pantheon Medical – Foot & Ankle, LLC and MediSource Partners, LLC.
• NuGenerex Health: MSO/HMO with Dr. Kiran Patel: Ancillary health management services for chronic conditions – 65 000+ Patient Population with Diabetes, Ophthalmology, Podiatry, Chronic Care Management (CCM)
Here is PART of an email(just general info) I got from Todd Falls today after I sent him Joe, EVH and Joe yet another CV report which left GNBT/NGIO out. They are appreciative of us catching these pieces and sending them there way.
Generex Biotechnology Corp. An integrated life sciences family of companies.
Today’s branches of Generex Biotechnology Corp. (GNBT) The “New” Generex & The NuGenerex Family of Subsidiary Companies Generex and its subsidiary companies have extensive patent portfolios, with intellectual property for composition of matter, formulation, design, and use in a number of therapeutic areas, across multiple indications. As described, we plan to build our legacy assets with the ultimate goal to spin-out such assets at the appropriate time, which have been incorporated into NuGenerex subsidiary companies in an effort to unlock the potential unrealized value of the intellectual property and commercial opportunities for these development companies in major markets for immuno-oncology, diabetes, and infectious disease testing:
• NuGenerex Therapeutics: Oral-lyn (Buccal Insulin) and RaidMist Buccal delivery technology
• NuGenerex Immuno-Oncology: Phase II AE37 + Keytruda in TNBC; Antigen Express (Ii-Key), Licensing, Partnerships, investor dividend paid (1:4) for spin-out
• NuGenerex Diagnostics: NGDx Express II rapid diagnostic tests for infectious disease.
The “New” Generex & The NuGenerex Family of Subsidiary Companies Through reorganization and acquisition, we are building the family of NuGenerex subsidiary companies to provide end-to-end solutions for physicians and patients. To that end, our subsidiary NuGenerex Distribution Solutions (NDS) has established a network of physicians, ancillary service providers, and patients through a Management Services Organization (MSO). As the MSO network currently consists of orthopedic surgeons and podiatrists, we have acquired and/or have agreements to acquire a number of revenue-generating companies that manufacture, market and distribute surgical and wound healing products. The acquisitions include Olaregen Therapeutix, a regenerative medicine company that has recently launched Excellagen wound conforming gel, which is FDA-cleared for the management of 17 wound healing indications, and Regentys, a clinical-stage development company with regenerative medicine technology for the treatment of inflammatory bowel diseases; Pantheon Medical, a manufacturer of patented, FDA-cleared foot & ankle kits with surgical plates, screws, and tools; and MediSource Partners, a licensed distributor of surgical supplies, orthopedic implants, and biologics, including human placental derived tissue products for regenerative medicine applications. Additionally, NDS will be launching a new software as a service (SaaS) business called DME-IQ that enables orthopedic surgeons to manage in-house programs for orthopedic durable medical equipment, including inventory controls, insurance adjudication, and patient billing. Together, under the banner of these subsidiary companies offer a range of products and services to meet the needs of our proprietary distribution channels. Cross selling of products and services will enhance the revenue opportunities for the entire family of NuGenerex subsidiaries.
Our corporate mission is to provide end-to-end solutions for physicians and patients through geographic expansion of our MSO model, diversification of management services offerings, the establishment of an HMO in partnership with Dr. Kiran Patel, and the proposed acquisition of an Accountable Care Organization for complex care.
The NuGenerex family of subsidiary companies offer a broad range of products and services to meet the needs of physicians and patients, including:
• Nugenerex Distribution Solutions: MSO, Ancillary Services, DME-IQ, and Surgical Products.
• NuGenerex Regenerative Medicine: Olaregen Therapetix, Regentys.
• NuGenerex Surgical Products: Pantheon Medical – Foot & Ankle, LLC and MediSource Partners, LLC.
• NuGenerex Health: MSO/HMO with Dr. Kiran Patel: Ancillary health management services for chronic conditions – 65 000+ Patient Population with Diabetes, Ophthalmology, Podiatry, Chronic Care Management (CCM)
